La Jolla Pharmaceutical Co (LJPC.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2014||Chairman of the Board|
|57||2012||President, Chief Executive Officer, Secretary, Director|
|62||2015||Chief Financial Officer|
|63||2017||Chief Operating Officer|
|48||2017||Chief Scientific Officer|
- BRIEF-La Jolla Pharmaceutical Co Announces Initiation Of Clinical Study Of LJPC‑401 In Patients With Beta Thalassemia
- BRIEF-La Jolla Pharma files for mixed shelf of up to $150 mln
- BRIEF-La Jolla reports Q3 loss $1.19/shr
- BRIEF-Prudential Financial reports 10.1 pct passive stake in La Jolla Pharmaceutical
- BRIEF-La Jolla Pharmaceutical Co announces intent to submit Marketing Authorization Application for LJPC-501